The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments ... and more than 200 others are making their way through (pre)clinical phases. 1 However, the ability of these ...

Cancer puts an increasing burden on our healthcare system and is a major cause of death. Therefore, novel approaches are required to improve cancer treatment. Cancer cells have several hallmarks ...

Figure 1: Domain architecture of the classic poly-ADP ... Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model proposed by Kleine et al.7 ...

We are getting questions from farmers and accountants wondering if Pandemic Assistance Revenue Program (PARP) payments are still going to be made in 2023. Many are tidying up taxes for 2023 ...

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib). Previously, several other firms were rumoured ...

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and ... tumours that carry BRCA 1/2 mutations.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in patients with advanced ovarian cancer.

PARP proteins are involved in DNA repair ... The small molecule works by inhibiting ALC1 (chromodomain-helicase-DNA-binding ...